🎉 M&A multiples are live!
Check it out!

Celltrion Valuation Multiples

Discover revenue and EBITDA valuation multiples for Celltrion and similar public comparables like Vivoryon Therapeutics, Galapagos, and Julphar.

Celltrion Overview

About Celltrion

Founded in 2002 in South Korea, Celltrion is one of the largest biosimilar manufacturers around the world. Biosimilar drug sales accounted for 87% of its total revenue in 2024. Europe is the largest market for its biosimilar drug sales, contributing more than 47% of its total revenue, followed by 37% from the North America region and 16% from emerging markets. Besides biosimilar manufacturing, Celltrion entered the contract manufacturing business in 2024.


Founded

1991

HQ

South Korea
Employees

n/a

Website

celltrion.com

Financials

LTM Revenue $2.9B

LTM EBITDA $904M

EV

$30.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Celltrion Financials

Celltrion has a last 12-month revenue (LTM) of $2.9B and a last 12-month EBITDA of $904M.

In the most recent fiscal year, Celltrion achieved revenue of $2.6B and an EBITDA of $784M.

Celltrion expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Celltrion valuation multiples based on analyst estimates

Celltrion P&L

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $2.9B XXX $2.6B XXX XXX XXX
Gross Profit $1.6B XXX $1.2B XXX XXX XXX
Gross Margin 54% XXX 47% XXX XXX XXX
EBITDA $904M XXX $784M XXX XXX XXX
EBITDA Margin 31% XXX 30% XXX XXX XXX
EBIT $625M XXX $361M XXX XXX XXX
EBIT Margin 22% XXX 14% XXX XXX XXX
Net Profit $505M XXX $310M XXX XXX XXX
Net Margin 17% XXX 12% XXX XXX XXX
Net Debt XXX XXX $854M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Celltrion Stock Performance

As of July 17, 2025, Celltrion's stock price is KRW 176800 (or $130).

Celltrion has current market cap of KRW 40.03T (or $29.3B), and EV of KRW 41.28T (or $30.3B).

See Celltrion trading valuation data

Celltrion Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$30.3B $29.3B XXX XXX XXX XXX $2.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Celltrion Valuation Multiples

As of July 17, 2025, Celltrion has market cap of $29.3B and EV of $30.3B.

Celltrion's trades at 11.6x EV/Revenue multiple, and 38.6x EV/EBITDA.

Equity research analysts estimate Celltrion's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Celltrion has a P/E ratio of 58.1x.

See valuation multiples for Celltrion and 12K+ public comps

Celltrion Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $29.3B XXX $29.3B XXX XXX XXX
EV (current) $30.3B XXX $30.3B XXX XXX XXX
EV/Revenue 10.4x XXX 11.6x XXX XXX XXX
EV/EBITDA 33.5x XXX 38.6x XXX XXX XXX
EV/EBIT 48.4x XXX 83.9x XXX XXX XXX
EV/Gross Profit 19.4x XXX n/a XXX XXX XXX
P/E 58.1x XXX 94.7x XXX XXX XXX
EV/FCF 63.8x XXX 72.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Celltrion Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Celltrion Margins & Growth Rates

Celltrion's last 12 month revenue growth is 20%

Celltrion's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Celltrion's rule of 40 is 63% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Celltrion's rule of X is 81% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Celltrion and other 12K+ public comps

Celltrion Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 20% XXX 20% XXX XXX XXX
EBITDA Margin 31% XXX 30% XXX XXX XXX
EBITDA Growth 43% XXX 27% XXX XXX XXX
Rule of 40 63% XXX 50% XXX XXX XXX
Bessemer Rule of X XXX XXX 81% XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX n/a XXX XXX XXX
S&M Expenses to Revenue XXX XXX 11% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 6% XXX XXX XXX
Opex to Revenue XXX XXX 33% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Celltrion Public Comps

See public comps and valuation multiples for Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Celltrion M&A and Investment Activity

Celltrion acquired  XXX companies to date.

Last acquisition by Celltrion was  XXXXXXXX, XXXXX XXXXX XXXXXX . Celltrion acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Celltrion

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Celltrion

When was Celltrion founded? Celltrion was founded in 1991.
Where is Celltrion headquartered? Celltrion is headquartered in South Korea.
Who is the CEO of Celltrion? Celltrion's CEO is Mr. Sung-Woo Ki.
Is Celltrion publicy listed? Yes, Celltrion is a public company listed on KRX.
What is the stock symbol of Celltrion? Celltrion trades under 068270 ticker.
When did Celltrion go public? Celltrion went public in 2005.
Who are competitors of Celltrion? Similar companies to Celltrion include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Celltrion? Celltrion's current market cap is $29.3B
What is the current revenue of Celltrion? Celltrion's last 12 months revenue is $2.9B.
What is the current revenue growth of Celltrion? Celltrion revenue growth (NTM/LTM) is 20%.
What is the current EV/Revenue multiple of Celltrion? Current revenue multiple of Celltrion is 10.4x.
Is Celltrion profitable? Yes, Celltrion is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Celltrion? Celltrion's last 12 months EBITDA is $904M.
What is Celltrion's EBITDA margin? Celltrion's last 12 months EBITDA margin is 31%.
What is the current EV/EBITDA multiple of Celltrion? Current EBITDA multiple of Celltrion is 33.5x.
What is the current FCF of Celltrion? Celltrion's last 12 months FCF is $474M.
What is Celltrion's FCF margin? Celltrion's last 12 months FCF margin is 16%.
What is the current EV/FCF multiple of Celltrion? Current FCF multiple of Celltrion is 63.8x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.